 |
Published Articles
Articles Published by CAP-Hepatitis C & CAP-Hepatitis C Medical Team Authors
- Viral
Hepatitis in Infants and Young Children: Risks, Recognition, & Prevention
Tina M. St. John, M.D.
Originally printed in Hepatitis
Magazine, Fall 2003. Reprinted with permission.
-
Chronic Hepatitis B and C in China
Tina M. St. John, M.D.
Originally published in Hepatitis
Magazine, Spring 2002. Reprinted with permission.
-
The Hepatitis C-Diabetes Connection
Tina M. St. John, M.D.
Originally published in Hepatitis
Magazine, "Doctor on Call," 2005. Reprinted with permission.
-
Expanding Waistlines Results in More Fatty Liver Disease
Tina M. St. John, MD
Originally published in Hepatitis
Magazine, "Doctor on Call," 2005. Reprinted with permission.
- Hepatitis
A: What You Don't Know Can Hurt You
Tina M. St. John, MD
Originally published in Hepatitis
Magazine, 2004. Reprinted with permission.
-
Why Am I So Itchy?
Tina M. St. John, MD
Originally published in Hepatitis
Magazine, "Doctor on Call," 2003. Reprinted with permission.
-
What Do I Tell The Kids?
Tina M. St. John, MD
Originally published in Hepatitis
Magazine, 2002. Reprinted with permission.
-
Women and Hepatitis: The Estrogen Connection
Tina M. St. John, MD
Originally published in Hepatitis
Magazine, 2004. Reprinted with permission.
- Molecular Epidemiology of Hepatitis C Virus Subtype 3a in Injecting Drug Users
Yoann Morice, Jean-Francois Cantaloube, Stephanie Beaucourt, et al. Journal
of Medical Virology. 2006 ;78:1296-1303.
Hepatitis C virus subtype 3a (HCV-3a) originates from Asia and has spread widely among injecting drug users as well as other patient groups in industrialized countries. HCV subtype 3a infection remains highly prevalent and frequently transmitted in the population of intravenous drug users. The objective of this study was to understand better the mechanisms of the worldwide HCV-3a epidemics in drug users.
-
Hepatitis C: Current Standards of Care and Future Perspectives
Robert G. Gish , M.D., California Pacific Medical Center
Member, CAP-Hepatitis C Medical Brainstorming Team
Hepatitis C affects approximately 4-5 million people in the United States with nearly 75% having long-term hepatitis C virus (HCV). Even with advances in treatment, about one half of patients will not achieve an SVR. Pegylated interferon and ribavirin combination therapy is currently the standard of care for the
treatment of chronic hepatitis C.
-
Future Therapies for Hepatitis C
Jean-Michel Pawlotsky and Robert G Gish.* Antivir Ther. 2006;11(4):397-408.
*Member, CAP-Hepatitis C Medical Brainstorming Team
Although pegylated interferon-a plus ribavirin has become the standard
for treating chronic hepatitis C virus infection, a substantial number
of patients do not tolerate therapy and require dose reduction or discontinuation,
or do not respond to this combination therapy. Thus, new therapeutic options
are needed. Read more.
- The
Hepatitis C Crisis
St. John TM, Sandt L.
Ethnicity and Disease. 2005 Spring;15(2 Suppl 2):S52-7.
An estimated 170 million persons (3% of the world's population) are infected
with the hepatitis C virus (HCV), and 3 to 4 million persons are newly
infected each year. Of those infected, 70%-85% develop chronic viremia
with the potential for devastating long-term sequelae, including chronic
liver disease, cirrhosis, hepatic failure, and hepatocellular carcinoma.
The passivity in the public health sector and in the medical community
at large with respect to hepatitis C portends a myriad of societal,
fiscal, and personal costs for the United States within the next two
decades unless immediate actions are taken to intervene in the natural
history of this emerging public health crisis.
To order a reprint of The Hepatitis C Crisis, email: lorren@hepcchallenge.org
|
 |
